Latest Developments

03 February 2011
A5 Laboratories has received approval letter for it’s containment level 2 facility.

MONTREAL, QUEBEC–(Marketwire – 02/03/11) – A5 Laboratories Inc. (A5 Labs) (OTC.BB:AFLB – News) announced today the office of Biohazard and Containment Safety

01 February 2011
A5 Laboratories, Inc. Announces Successful Production of VI-1718 Interferon Product

MONTREAL, QUEBEC–(Marketwire – 02/01/11) – A5 Laboratories Inc. (A5 Labs) (OTC.BB:AFLB – News) announced today the successful production of its VI-1718 interferon product by its European manufacturing partner.

Current Stock Info

AFLB.OB0.00  chart+0.00
1970-01-01 00:00

Leadership

President & CEO

Richard Azani, Ph.D.

Richard Azani PhD. has served as the President & CEO of Alison Pharma in Montreal since its inception in 2003. His executive resume in the pharmaceutical industry stretches back more than 15 years when he became the VP of Production at ACP Chemicals, a major Canadian raw-material and in-process chemicals manufacturer and distributor.

Mr. Azani has since served as VP of Analex Laboratory, specializing in pharmaceutical, food, and environmental testing, and President & CEO of Actilab Pharma, Inc., prior to his position with VNP.

Mr. Azani holds a PhD. from the University of Toulouse (France) and has completed post-doctoral work at McGill University in Montreal.

Management

  • Gisele Matni, Ph.D., Pharm.D. VP – Research and Development
  • Thi Man N’Guyen, M.Sc. – Director of Production
  • S. Berrada Ph.D, – Quality Assurance Director
  • C. Rofir, M.Sc. – Quality Control Director